InRAD international registry for Alzheimer's disease and related dementias
Official title: The International Registry for Alzheimer's Disease and Other Dementias (InRAD): An International Registry Observational Study Dedicated to Evaluating Outcomes Data in Alzheimer's Disease
Run by Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · NCT07213700 · Data updated 2026-11-12
This project will collect routine medical information over time to see how Alzheimer's disease, mild cognitive impairment, and related dementias progress and how current treatments are tolerated in adults.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50000 (estimated) |
| Sponsor | Stichting International Registry for Alzheimer's Disease and other Dementias Foundation Academic / other |
| Locations | 23 sites (Melbourne and 22 other locations) |
| Status | Recruiting |
| Started | March 30, 2026 |
| Main results expected | January 2036 |
| Study ends | January 2036 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT07213700 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults undergoing diagnostic work-up for Alzheimer's disease or with a confirmed AD diagnosis (treated or untreated) who receive care at an InRAD-affiliated center and can provide informed consent are eligible.
✕Probably not a fit
People who cannot or will not provide informed consent, or who do not attend an InRAD center, are unlikely to receive direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The InRAD Observational Study is a prospective, non-interventional, multinational registry that collects real-world clinical data from adults undergoing diagnostic work-up for or living with Alzheimer's disease. Participating centers record demographics, comorbidities, diagnostic and monitoring tests, medication exposures, cognitive and functional measures, and adverse events during routine care, typically with at least annual visits. Data are pseudonymized and pooled to allow comparison of disease trajectories, treatment safety, and outcomes across countries and regions over many years. Operational management and system support are provided by the InRAD Foundation while individual centers remain the data controllers.
Why it matters
Potential benefit: If successful, the registry could improve understanding of long-term disease course and treatment safety, helping clinicians make better care and monitoring decisions for patients with dementia.
How similar studies have gone: Large observational registries and consortia (for example ADNI and national dementia registries) have produced useful insights into progression and treatment effects, so this registry approach is established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be undergoing diagnostic work-up for Alzheimer's disease (AD), OR * Have a confirmed diagnosis of AD (whether currently treated with an AD-specific treatment, or untreated), * Be attending an InRAD Center, * Have provided informed consent for long-term follow-up Exclusion Criteria: -Any patient or legal representative who is unable or unwilling to provide a signed informed consent form The protocol does not specify a lower or upper age limit. Participants are expected to be predominantly adults, and can include younger adults with early-onset or genetically determined Alzheimer's disease (e.g. Down syndrome-associated Alzheimer's disease).
Where it's running
-
Alfred Hospital
Melbourne, Australia Recruiting -
Medical University of Graz
Graz, Austria Recruiting -
Kardinal Schwarzenberg Klinikum
Schwarzach, Austria Recruiting -
UZLeuven
Leuven, Belgium Recruiting -
Irmandade da Santa Casa de São Paulo
São Paulo, Brazil Recruiting -
Motol and Homolka University Hospital (UHM)
Prague, Czechia Recruiting
Show 17 more locations
-
Ain Shams University
Cairo, Egypt Recruiting -
Aiginition Hospital
Athens, Greece Recruiting -
Panhellenic Federation of Alzheimer's Disease and Related Disorders
Thessaloniki, Greece Recruiting -
The Adelaide and Meath Hospital
Dublin, Ireland Recruiting -
B.R.A.N.D. Center - Neurologia Universitaria - Policinico Foggia
Foggia, Italy Recruiting -
Ospedale San Raffaele
Milan, Italy Recruiting -
Stichting Amsterdam UMC (location VUmc) - ABOARD Cohort
Amsterdam, Netherlands Recruiting -
Stichting Amsterdam UMC (location VUmc) - Amsterdam Dementia Cohort
Amsterdam, Netherlands Recruiting -
NeuroProtect
Warsaw, Poland Recruiting -
Hospital de Santo António
Porto, Portugal Recruiting -
County Emergency Clinic Hospital Brasov/Spitalul Clinic Judetean de Urgenta Brasov
Brasov, Romania Recruiting -
Saint Luke Hospital for Chronic Disease-Geriatrics and Gerontology II
Bucharest, Romania Recruiting -
Fundatia Ana Aslan International
Bucharest, Romania Recruiting -
King Faisal Specialist Hospital
Riyadh, Saudi Arabia Recruiting -
Fundació ACE, Institut Català de Neurociències Aplicades
Barcelona, Spain Recruiting -
New Taipei Municipal TuCheng Hospital
New Taipei City, Taiwan Recruiting -
Istanbul University Çapa Hospital
Istanbul, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Scientific Officer
- Email: office@inradnetwork.org
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Aging Brain Health Initiative in Fujian
This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.
-
Digital tools to predict Alzheimer's biology from risk factors
This study tests a digital, AI-based tool that analyzes modifiable and non-modifiable risk factors to see if it can predict biological changes linked to Alzheimer's disease in adults with MCI or SCD.
-
Community screening with blood biomarkers for Alzheimer's in older adults
This project will test whether two blood biomarkers (pTau217/Aβ42 ratio and GFAP) can detect Alzheimer's disease or mild cognitive impairment in community-dwelling older adults.
-
Online positive psychology program to support thinking and brain health in early memory changes
This study will test whether an online positive psychology program can improve thinking, brain function, and wellbeing in older adults with early memory problems (Subjective Cognitive Decline or Mild Cognitive Impairment).
-
Personalized digital training for cognitive fitness in people with mild cognitive impairment
This study tests whether a personalized home-based digital program (RICORDO) helps people aged 50 and older with mild cognitive impairment or subjective cognitive decline manage their health and daily life better than a paper-and-video education program.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.